Wei Yu

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 596 citations

Medicine, Oncology, Pharmacology +17

A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

Muralidhar Beeram, Ian E. Krop, Howard A. Burris et al. · Cancer · 2012 · 103 citations · Full text

Medicine, Oncology, Pharmacology +13

Mitochondrial NDUFA4L2 attenuates the apoptosis of nucleus pulposus cells induced by oxidative stress via the inhibition of mitophagy

Wenning Xu, Huo‐Liang Zheng, Runze Yang et al. · Experimental & Molecular Medicine · 2019 · 103 citations · Full text

Life Sciences, Biochemistry, Cell Biology +17

MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors

Christopher J. Sweeney, John D. Hainsworth, Ron Bose et al. · Journal of Clinical Oncology · 2023 · 67 citations · Full text

Medicine, Oncology, Solid Tumor Pharmacotherapy +1

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies

Ravi Salgia, Premal H. Patel, John Bothos et al. · Clinical Cancer Research · 2014 · 65 citations · Full text

Medicine, Oncology, Pharmacology +17